The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
about
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice.NAFLD: Is There Anything New under the Sun?Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway
P2860
The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The Dipeptidyl Peptidase-4 Inh ...... Fatty Liver Disease Model Mice
@en
type
label
The Dipeptidyl Peptidase-4 Inh ...... Fatty Liver Disease Model Mice
@en
prefLabel
The Dipeptidyl Peptidase-4 Inh ...... Fatty Liver Disease Model Mice
@en
P2093
P2860
P356
P1476
The Dipeptidyl Peptidase-4 Inh ...... Fatty Liver Disease Model Mice
@en
P2093
Hiroyasu Sakai
Hisataka Moriwaki
Masahito Shimizu
Takahiro Kochi
Takayasu Ideta
Tsuneyuki Miyazaki
Yohei Shirakami
P2860
P304
29207-29218
P356
10.3390/IJMS161226156
P407
P577
2015-12-08T00:00:00Z